Manatuck Hill Partners’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-75,000
Closed -$38K – 107
2017
Q2
$38K Hold
75,000
– – 0.02% 81
2017
Q1
$32K Hold
75,000
– – 0.01% 87
2016
Q4
$41K Hold
75,000
– – 0.02% 84
2016
Q3
$39K Buy
+75,000
New +$20.5K 0.02% 92

Manatuck Hill Partners's AST.WS Position: Q3 2017 in Review

Manatuck Hill Partners sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 75,000 shares — an estimated $38K sold.

Manatuck Hill Partners first reported a position in AST.WS in Q3 2016 and held it in 4 quarters. The position peaked at $41K in Q4 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Manatuck Hill Partners reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • Manatuck Hill Partners sold 75,000 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $38K.
  • Manatuck Hill Partners first reported a position in Asterias Biotherapeutics Warrants in Q3 2016 and held it in 4 quarters.
  • Manatuck Hill Partners's Asterias Biotherapeutics Warrants position peaked at $41K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on Manatuck Hill Partners's 13F filing for Q3 2017, filed 14 Nov 2017.